Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDTXNASDAQ:ENGNNASDAQ:HUMANASDAQ:TCRR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTXCidara Therapeutics$46.84+4.2%$23.26$10.14▼$56.83$563.97M0.79130,046 shs3.47 million shsENGNenGene$2.99-1.0%$3.67$2.65▼$11.00$154.34M-0.4128,771 shs48,249 shsHUMAHumacyte$2.23+0.9%$2.02$1.15▼$9.79$342.81M1.993.82 million shs1.45 million shsTCRRTCR2 Therapeutics$1.48$1.65$0.82▼$3.88$58.11M1.95494,777 shsN/A2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTXCidara Therapeutics+113.84%+100.58%+85.13%+104.04%+286.83%ENGNenGene-4.13%-8.76%-28.77%-38.74%-66.44%HUMAHumacyte-4.33%-8.30%-12.65%-23.26%-57.25%TCRRTCR2 Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDTXCidara Therapeutics3.7521 of 5 stars3.62.00.04.63.10.00.0ENGNenGene2.7907 of 5 stars3.53.00.00.01.92.50.6HUMAHumacyte2.0989 of 5 stars3.51.00.00.01.52.50.6TCRRTCR2 TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDTXCidara Therapeutics 3.11Buy$53.7114.68% UpsideENGNenGene 3.00Buy$23.29678.79% UpsideHUMAHumacyte 3.00Buy$11.71425.30% UpsideTCRRTCR2 Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TCRR, CDTX, ENGN, and HUMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025CDTXCidara TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$35.00 ➝ $75.006/24/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $68.006/23/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$36.00 ➝ $54.006/23/2025CDTXCidara TherapeuticsWBB SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy$45.006/18/2025CDTXCidara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$41.006/10/2025CDTXCidara TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight6/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/4/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$35.00 ➝ $36.006/2/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$47.005/27/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$47.005/23/2025CDTXCidara TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$31.00 ➝ $35.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDTXCidara Therapeutics$1.27M462.87N/AN/A$14.92 per share3.14ENGNenGeneN/AN/AN/AN/A$4.45 per shareN/AHUMAHumacyte$517K669.08N/AN/A($0.41) per share-5.44TCRRTCR2 TherapeuticsN/AN/AN/AN/A$2.58 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDTXCidara Therapeutics-$169.83M-$29.47N/AN/AN/AN/A-73.04%-54.28%8/12/2025 (Estimated)ENGNenGene-$55.14M-$1.65N/AN/AN/AN/A-32.60%-28.26%N/AHUMAHumacyte-$148.70M-$0.69N/AN/AN/AN/AN/A-73.59%8/12/2025 (Estimated)TCRRTCR2 Therapeutics-$151.82M-$4.20N/AN/AN/AN/A-97.81%-69.35%N/ALatest TCRR, CDTX, ENGN, and HUMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/10/2025Q2 2025ENGNenGene-$0.4768-$0.51-$0.0332-$0.51N/AN/A5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million5/8/2025Q1 2025CDTXCidara Therapeutics-$5.45-$1.66+$3.79-$1.66N/AN/A3/28/2025Q4 2024HUMAHumacyte-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDTXCidara TherapeuticsN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDTXCidara TherapeuticsN/A3.873.87ENGNenGene0.0912.6612.66HUMAHumacyte0.363.683.28TCRRTCR2 TherapeuticsN/A2.962.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDTXCidara Therapeutics35.82%ENGNenGene64.16%HUMAHumacyte44.71%TCRRTCR2 Therapeutics64.76%Insider OwnershipCompanyInsider OwnershipCDTXCidara Therapeutics7.64%ENGNenGene10.40%HUMAHumacyte5.10%TCRRTCR2 Therapeutics25.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDTXCidara Therapeutics9012.55 million11.59 millionNo DataENGNenGene3151.10 million45.79 millionN/AHUMAHumacyte150155.12 million147.21 millionOptionableTCRRTCR2 Therapeutics13739.26 million29.44 millionNot OptionableTCRR, CDTX, ENGN, and HUMA HeadlinesRecent News About These CompaniesTCR2 Therapeutics gets grant for recombinant nucleic acid encoding TCR fusion protein for cancer treatmentApril 17, 2024 | pharmaceutical-technology.comPoseida Therapeutics Inc Ordinary Shares PSTXFebruary 25, 2024 | morningstar.comDICE Therapeutics Inc.June 20, 2023 | wsj.comAdaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy CompanyJune 1, 2023 | finance.yahoo.comTCR2 Therapeutics Insider Trades Send a SignalMay 16, 2023 | benzinga.comRecap: TCR2 Therapeutics Q1 EarningsMay 12, 2023 | msn.com10-Q: TCR2 THERAPEUTICS INC.May 11, 2023 | marketwatch.comTCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 11, 2023 | finance.yahoo.comCompanies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite RiskyApril 15, 2023 | finance.yahoo.comMizuho Downgrades Tcr2 Therapeutics (TCRR)March 25, 2023 | msn.comTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho SecuritiesMarch 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)March 23, 2023 | markets.businessinsider.comTCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateMarch 23, 2023 | finanznachrichten.deTCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateMarch 23, 2023 | finance.yahoo.comWhat To Know About Jefferies's Downgrade of TCR2 TherapeuticsMarch 9, 2023 | msn.com4 Analysts Have This to Say About TCR2 TherapeuticsMarch 9, 2023 | markets.businessinsider.comTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. WainwrightMarch 8, 2023 | markets.businessinsider.comShareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with AdaptimmuneMarch 6, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. BuyoutMarch 6, 2023 | benzinga.comWhy Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?March 6, 2023 | investorplace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTCRR, CDTX, ENGN, and HUMA Company DescriptionsCidara Therapeutics NASDAQ:CDTX$46.84 +1.89 (+4.20%) Closing price 04:00 PM EasternExtended Trading$45.65 -1.19 (-2.54%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.enGene NASDAQ:ENGN$2.99 -0.03 (-0.99%) Closing price 04:00 PM EasternExtended Trading$2.98 -0.01 (-0.17%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Humacyte NASDAQ:HUMA$2.23 +0.02 (+0.90%) Closing price 04:00 PM EasternExtended Trading$2.26 +0.04 (+1.57%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.TCR2 Therapeutics NASDAQ:TCRRTCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
